Simbol | Kap Pasar | Harga | Perubahan % | Volume | Volume Relatif | P/E | EPS terdilusi TTM | Pertumbuhan EPS terdilusi TTM YoY | Imbal hasil dividen % TTM | Sektor | Penilaian Analis |
---|---|---|---|---|---|---|---|---|---|---|---|
LLYDELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 (USD) DR | 720,65 T ARS | 13,450 USD | +1,89% | 205 | 0,47 | 104,38 | 124,85 ARS | +178,70% | 0,34% | Teknologi Kesehatan | — |
LLYELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 DR | 720,65 T ARS | 15.725,000 ARS | +0,96% | 4,31 K | 0,67 | 125,95 | 124,85 ARS | +564,33% | 0,34% | Teknologi Kesehatan | — |
JNJDJOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHS(USD) DR | 370,29 T ARS | 10,100 USD | +1,00% | 4,98 K | 4,12 | 31,89 | 306,92 ARS | +50,08% | 1,66% | Teknologi Kesehatan | — |
JNJJOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHS DR | 370,29 T ARS | 11.725,000 ARS | −0,42% | 61,92 K | 0,71 | 38,20 | 306,92 ARS | +257,75% | 1,66% | Teknologi Kesehatan | — |
DJNJ3JOHNSON & JOHNSON CEDEAR(REPR 6.95% BDS) DR | 370,29 T ARS | 1.315,000 ARS | +5,20% | 11 | 0,76 | — | — | — | — | Teknologi Kesehatan | — |
ABBVDABBVIE INC CEDEAR EA 10 REP 1 COM(USD) DR | 317,12 T ARS | 17,250 USD | +0,58% | 10 | 0,15 | 7,13 | 2.343,37 ARS | +18,73% | 1,73% | Teknologi Kesehatan | — |
ABBVABBVIE INC CEDEAR EACH 10 REPR 1 COM DR | 317,12 T ARS | 20.375,000 ARS | +0,49% | 1,39 K | 1,13 | 8,69 | 2.343,37 ARS | +183,01% | 1,73% | Teknologi Kesehatan | — |
MRKDMERCK & CO INC CEDEAR EAC 5 RE 1 (USD) DR | 259,1 T ARS | 20,200 USD | −0,98% | 214 | 4,18 | 22,16 | 883,37 ARS | +319,19% | 1,62% | Teknologi Kesehatan | — |
MRKMERCK & CO INC CEDEAR (5 REP 1 USD0.50) DR | 259,1 T ARS | 22.750,000 ARS | −1,30% | 8,9 K | 5,41 | 25,75 | 883,37 ARS | +899,22% | 1,62% | Teknologi Kesehatan | — |
AZNDASTRAZENECA PLC CEDEAR EA RE 0.5 ADR (USD) DR | 215,79 T ARS | 33,800 USD | −1,74% | 14 | 0,52 | 48,32 | 677,80 ARS | +64,44% | 1,46% | Teknologi Kesehatan | — |
AZNASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25 DR | 215,79 T ARS | 40.350,000 ARS | +3,20% | 291 | 0,25 | 59,53 | 677,80 ARS | +291,99% | 1,46% | Teknologi Kesehatan | — |
NVSDNOVARTIS AG CEDEAR EAC 4 REP 1(USD) DR | 203,79 T ARS | 25,300 USD | −0,39% | 1 | 0,31 | 2,83 | 8.672,72 ARS | +140,89% | 3,70% | Teknologi Kesehatan | — |
NVSNOVARTIS AG CEDEAR EACH 4 REP 1 DR | 203,79 T ARS | 29.150,000 ARS | −2,83% | 494 | 2,29 | 3,36 | 8.672,72 ARS | +474,20% | 3,70% | Teknologi Kesehatan | — |
PFEDPFIZER INC CEDEAR 4 REP 1 ORD USD0.05(USD) DR | 155,9 T ARS | 6,770 USD | −0,44% | 394 | 0,18 | 27,95 | 234,71 ARS | +35,96% | 3,12% | Teknologi Kesehatan | — |
PFEPFIZER INC CEDEAR EACH 4 REP 1 ORD USD0.05 DR | 155,9 T ARS | 7.870,000 ARS | −0,88% | 38,64 K | 1,54 | 33,53 | 234,71 ARS | +224,10% | 3,12% | Teknologi Kesehatan | — |
BMYDBRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1 USD DR | 119,42 T ARS | 19,500 USD | +2,09% | 5 | 0,61 | — | −1.078,84 ARS | −253,68% | 2,01% | Teknologi Kesehatan | — |
BMYBRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1 DR | 119,42 T ARS | 22.500,000 ARS | −2,07% | 412 | 0,87 | — | −1.078,84 ARS | −466,33% | 2,01% | Teknologi Kesehatan | — |
GSKDGSK PLC CEDEAR EACH REPR 1/4 ADR (USD) DR | 71,24 T ARS | 8,150 USD | −4,12% | 93 | 1,58 | 25,65 | 307,84 ARS | −37,30% | 3,13% | Teknologi Kesehatan | — |
GSKGSK PLC CEDEAR EACH REPR 1/4 ADR DR | 71,24 T ARS | 10.025,000 ARS | −0,74% | 130 | 0,21 | 32,57 | 307,84 ARS | +49,45% | 3,13% | Teknologi Kesehatan | — |
BIIBDBIOGEN INC CEDEAR EAC 13 RE 1 COM(USD) DR | 21,42 T ARS | 11,550 USD | −0,43% | 9 | 0,53 | 16,09 | 695,64 ARS | +96,62% | 0,00% | Teknologi Kesehatan | — |
BIIBBIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005 DR | 21,42 T ARS | 12.950,000 ARS | −1,89% | 988 | 1,64 | 18,62 | 695,64 ARS | +368,68% | 0,00% | Teknologi Kesehatan | — |
RICHLABORATORIOS RICHMOND SACIF | 143,74 B ARS | 1.775,000 ARS | −0,84% | 10,23 K | 0,67 | 18,43 | 96,29 ARS | — | 0,00% | Teknologi Kesehatan | — |
ROSEINSTITUTO ROSENBUCH SA DE BIOLOGIA | 4,6 B ARS | 108,000 ARS | 0,00% | 11,95 K | 3,24 | 25,30 | 4,27 ARS | +64,50% | 0,00% | Teknologi Kesehatan | — |